Edition:
United Kingdom

DelMar Pharmaceuticals Inc (DMPI.OQ)

DMPI.OQ on NASDAQ Stock Exchange Capital Market

0.77USD
21 Aug 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$0.77
Open
$0.77
Day's High
$0.78
Day's Low
$0.77
Volume
44,022
Avg. Vol
149,336
52-wk High
$8.50
52-wk Low
$0.71

Latest Key Developments (Source: Significant Developments)

DelMar Pharmaceuticals Enrolls First Patient In The Recently-Approved Adjuvant Setting Arm Of Phase 2 Study Of VAL-083
Wednesday, 24 Jul 2019 

July 24 (Reuters) - DelMar Pharmaceuticals Inc ::DELMAR PHARMACEUTICALS ENROLLS FIRST PATIENT IN THE RECENTLY-APPROVED ADJUVANT SETTING ARM OF PHASE 2 STUDY OF VAL-083 FOR THE TREATMENT OF MGMT-UNMETHYLATED GLIOBLASTOMA MULTIFORME.DELMAR PHARMACEUTICALS INC - DELMAR IS ACTIVELY ENROLLING PATIENTS FOR BOTH TRIAL ARMS OF CLINICAL STUDY AT MDACC..DELMAR PHARMACEUTICALS INC - CONDUCTING A PHASE 2 CLINICAL STUDY OF VAL-083 AS FIRST LINE TREATMENT FOR GBM IN COMBINATION WITH RADIOTHERAPY IN CHINA.  Full Article

Delmar Pharmaceuticals Files Prospectus Relates To Resale By Selling Stockholders Of Up To 760,500 Shares Of Co's Common Stock - SEC Filing
Tuesday, 25 Jun 2019 

June 25 (Reuters) - DelMar Pharmaceuticals Inc ::DELMAR PHARMACEUTICALS FILES PROSPECTUS RELATES TO RESALE BY SELLING STOCKHOLDERS OF UP TO 760,500 SHARES OF CO'S COMMON STOCK - SEC FILING.  Full Article

Delmar Pharmaceuticals Appoints Oppenheimer & Co Inc As Strategic Advisor
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - DelMar Pharmaceuticals Inc ::DELMAR PHARMACEUTICALS APPOINTS OPPENHEIMER & CO. INC. AS STRATEGIC ADVISOR.DELMAR PHARMACEUTICALS - FIRM WILL WORK ON BEHALF OF CO TO MANAGE EXPLORATION & EVALUATION OF RANGE OF STRATEGIC OPPORTUNITIES.  Full Article

Delmar Appoints Saiid Zarrabian Full-Time President And CEO
Tuesday, 22 May 2018 

May 22 (Reuters) - DelMar Pharmaceuticals Inc ::DELMAR APPOINTS SAIID ZARRABIAN TO FULL-TIME PRESIDENT AND CEO.DELMAR PHARMACEUTICALS - ZARRABIAN HAD PREVIOUSLY SERVED AS INTERIM PRESIDENT AND CEO SINCE NOVEMBER 2017.  Full Article

Delmar Pharmaceuticals To Increase Number Of Authorized Shares Of Stock, Par Value Of $0.001, Per Share From 50 Mln Shares To 70 Mln Shares
Friday, 13 Apr 2018 

April 13 (Reuters) - DelMar Pharmaceuticals Inc ::TO INCREASE NUMBER OF AUTHORIZED SHARES OF STOCK, PAR VALUE OF $0.001, PER SHARE FROM 50 MILLION SHARES TO 70 MILLION SHARES.  Full Article

Delmar Pharmaceuticals' interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on Nov 14
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Delmar Pharmaceuticals Inc :Delmar Pharmaceuticals Inc interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on nov 14 - SEC Filing.  Full Article

Delmar Pharmaceuticals names Saiid Zarrabian interim CEO
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Delmar Pharmaceuticals Inc :Delmar Pharmaceuticals appoints Saiid Zarrabian as interim chief executive officer.Jeffrey Bacha, cofounder of Co, will continue in role as president and in newly created position of chief operating officer​.Zarrabian and Bacha will continue to serve on company's board of directors​.  Full Article

DelMar Pharmaceuticals CEO Jeffrey​ Bacha buys 10,000 shares of co's common stock on Oct 6
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - DelMar Pharmaceuticals Inc :DelMar Pharmaceuticals Inc <<>> CEO Jeffrey​ Bacha reports open market puchase of 10,000 shares of co's common stock on Oct 6 - SEC filing.  Full Article